Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2020 · 10-Q
Revenue$314.00K$314.00K−51.8% vs Q2 2019 Net Income-$3.76M-$3.76MN/M vs Q2 2019 EPS Diluted-$0.69-$0.69N/M vs Q2 2019 Operating Income-$3,155,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,607,000N/M Margins · derivedOperating margin-1004.8%−388.0 pt vs Q2 2019
Net margin-1198.1%−511.6 pt vs Q2 2019
ended Dec 31, 2019 · filed Feb 14, 2020 · 45 d after period end